Paper Details

  1. Home
  2. Paper Details

Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study.

Author: GökeBurkhard, OchsenkühnThomas, SackmannMichael

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study explores the effectiveness of infliximab, a medication that targets a protein involved in inflammation, in treating patients with acute ulcerative colitis (inflammation of the colon) who are unable to take steroids. The study aims to determine if infliximab can help these patients achieve remission, even without needing steroid treatment.
Paper Details　
Original Abstract of the Article :
Therapeutic alternatives for patients with acute ulcerative colitis in whom steroids would usually be contraindicated are rare. The antibody to tumor necrosis factor alpha, infliximab, has shown to be effective in the treatment of steroid-refractory ulcerative colitis in pilot studies. We therefore ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/00042737-200411000-00014

データ提供：米国国立医学図書館（NLM）

Infliximab: A New Hope for Ulcerative Colitis?

[Ulcerative colitis] is a chronic inflammatory bowel disease that can be difficult to treat. Steroids are often used for flares, but they can have side effects, and sometimes patients don't respond. This study explores the potential of infliximab, an antibody to tumor necrosis factor alpha, as a treatment option for patients with acute ulcerative colitis, even those who aren't steroid-refractory. Imagine a camel traversing a harsh desert, seeking a oasis of relief. That's what infliximab aims to provide for these patients.

A Novel Approach to Treating Ulcerative Colitis

The researchers conducted a [randomized pilot study] to evaluate the efficacy of infliximab in achieving remission in patients with acute ulcerative pancolitis. This study involved comparing infliximab to standard treatment options. The results revealed that infliximab can be effective in inducing remission in patients with acute ulcerative pancolitis, even those who aren't steroid-refractory. This finding offers a potential alternative treatment option for these patients, expanding the landscape of therapeutic options.

The Potential Benefits for Patients

The study suggests that infliximab could be a viable treatment option for patients with acute ulcerative colitis, even those who aren't steroid-refractory. This could provide relief from the debilitating symptoms of this condition, potentially improving their quality of life. It's like a camel discovering a new water source in the desert, offering hope and a chance for a brighter future.

Dr. Camel's Conclusion

This research sheds light on the potential of infliximab as a valuable treatment option for patients with acute ulcerative colitis, particularly those who aren't responding to traditional therapies. It's like finding a hidden oasis in the vast desert, providing hope and a chance for a better life.
Date :
  1. Date Completed 2005-03-17
  2. Date Revised 2019-09-06
Further Info :

Pubmed ID

15489577

DOI: Digital Object Identifier

10.1097/00042737-200411000-00014

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.